On the Need to Compensate for Edema-Induced Dose Reductions in Preplanned 131Cs Prostate Brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 70, Issue 1, 2008, Pages 303-310

  Chen, Z Jay ^a   Deng, Jun ^a   Roberts, Kenneth ^a   Nath, Ravinder ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

125I; 131Cs; Edema induced dose reduction; Prostate brachytherapy; Prostate edema

Indexed keywords

PROSTATE BRACHYTHERAPY; PROSTATE EDEMA;

IMPLANTS (SURGICAL); IRRADIATION; PATIENT MONITORING; RADIOTHERAPY;

TUMORS;

CESIUM; CESIUM 131; IODINE 125; PALLADIUM 103; UNCLASSIFIED DRUG;

ARTICLE; CANCER SURGERY; DOSIMETRY; DRUG DOSE REDUCTION; EDEMA; HUMAN; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIOISOTOPE THERAPY; TREATMENT PLANNING;

ALGORITHMS; BRACHYTHERAPY; CESIUM RADIOISOTOPES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; EDEMA; HUMANS; MALE; PROSTATIC DISEASES; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RELATIVE BIOLOGICAL EFFECTIVENESS; TIME FACTORS;

EID: 37049028133     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.09.007     Document Type: Article

References (42)

1. Roy J.N., Wallner K.E., Chiu-Tsao S.T., et al. CT-based optimized planning for transperineal prostate implant with customized template. Int J Radiat Oncol Biol Phys 21 (1991) 483-489
2. Stock R.G., Stone N.N., Wesson M.F., et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 32 (1995) 219-225
3. Zelefsky M.J., Yamada Y., Marion C., et al. Improved conformality and decreased toxicity with intraoperative computer-optimized transperineal ultrasound-guided prostate brachytherapy. Int J Radiat Oncol Biol Phys 55 (2003) 956-963
4. Waterman F.M., Yue N., Corn B.W., et al. Edema associated with I-125 or Pd-103 prostate brachytherapy and its impact on post-implant dosimetry: An analysis based on serial CT acquisition. Int J Radiat Oncol Biol Phys 41 (1998) 1069-1077
5. Moerland M.A., Wijrdeman H.K., Beersma R., et al. Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging. Int J Radiat Oncol Biol Phys 37 (1997) 927-933
6. Narayana V., Roberson P.L., Pu A.T., et al. Impact of differences in ultrasound and computed tomography volumes on treatment planning of permanent prostate implants. Int J Radiat Oncol Biol Phys 37 (1997) 1181-1185
7. Leclerc G., Lavallee M.C., Roy R., et al. Prostatic edema in 125I permanent prostate implants: Dynamic dosimetry taking volume changes into account. Med Phys 33 (2006) 574-583
8. Willins J., and Wallner K. Time-dependent changes in CT-based dosimetry of I-125 prostate brachytherapy. Radiat Oncol Invest 6 (1998) 157-160
9. Merrick G.S., Butler W.M., Dorsey A.T., et al. Influence of timing on the dosimetric analysis of transperineal ultrasound-guided, prostatic conformal brachytherapy. Radiat Oncol Invest 6 (1998) 182-190
10. Prestidge B.R., Bice W.S., Kiefer E.J., et al. Timing of computed tomography-based postimplant assessment following permanent transperineal prostate brachytherapy. Int J Radiat Oncol Biol Phys 40 (1998) 1111-1115
11. 103Pd prostate implants. Med Phys 26 (1999) 763-767
12. 103PD prostate seed implants. Int J Radiat Oncol Biol Phys 45 (1999) 1063-1072
13. Chen Z., Yue N., Wang X., et al. Dosimetric effects of edema in permanent prostate seed implants: A rigorous solution. Int J Radiat Oncol Biol Phys 47 (2000) 1405-1419
14. 131Cs (model CS-1) seeds. Med Phys 33 (2006) 968-975
15. Lee E.K., and Zaider M. On the determination of an effective planning volume for permanent prostate implants. Int J Radiat Oncol Biol Phys 49 (2001) 1197-1206
16. Wilkinson D.A., Lee E.J., Ciezki J.P., et al. Dosimetric comparison of pre-planned and OR-planned prostate seed brachytherapy. Int J Radiat Oncol Biol Phys 48 (2000) 1241-1244
17. Potters L., Calguaru E., Thornton K.B., et al. Toward a dynamic real-time intraoperative permanent prostate brachytherapy methodology. Brachytherapy 2 (2003) 172-180
18. Stone N.N., Hong S., Lo Y.C., et al. Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy. Brachytherapy 2 (2003) 17-25
19. Gewanter R.M., Wuu C., Laguna J.L., et al. Intraoperative preplanning for transperineal ultrasound-guided permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 48 (2000) 377-380
20. Yamada Y., Potters L., Zaider M., et al. Impact of intraoperative edema during transperineal permanent prostate brachytherapy on computer-optimized and preimplant planning techniques. Am J Clin Oncol 26 (2003) e130-e135
21. Nath R., Roberts K., Ng M., et al. Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine-125 interstitial implants. Med Phys 25 (1998) 2293-2307
22. 125iodine implantation of the prostate for clinically localized prostatic cancer. J Urol 158 (1997) 23-30
23. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41 (1998) 101-108
24. Potters L., Cao Y., Calugaru E., et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 50 (2001) 605-614
25. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the American Association of Physicists in Medicine (AAPM) Radiation Therapy Committee Task Group No. 43. Med Phys 22 (1995) 209-234
26. Fowler J.F. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62 (1989) 679-694
27. Dale R.G. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 58 (1985) 515-528
28. Chen Z., and Nath R. Biologically effective dose (BED) for interstitial seed implants containing a mixture of radionuclides with different half-lives. Int J Radiat Oncol Biol Phys 55 (2003) 825-834
29. Dale R.G., Jones B., and Coles I.P. Effect of tumour shrinkage on the biological effectiveness of permanent brachytherapy implants. Br J Radiol 67 (1994) 639-645
30. 103Pd. Phys Med Biol 46 (2001) 2557-2569
31. Brenner D.J., and Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43 (1999) 1095-1101
32. Fowler J., Chappell R., and Ritter M. Is alpha/beta for prostate tumors really low?. Int J Radiat Oncol Biol Phys 50 (2001) 1021-1031
33. Wang J.Z., Guerrero M., and Li X.A. How low is the alpha/beta ratio for prostate cancer?. Int J Radiat Oncol Biol Phys 55 (2003) 194-203
34. Wang J.Z., Li X.A., Yu C.X., et al. The low alpha/beta ratio for prostate cancer: What does the clinical outcome of HDR brachytherapy tell us?. Int J Radiat Oncol Biol Phys 57 (2003) 1101-1108
35. Nahum A.E., Movsas B., Horwitz E.M., et al. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: Implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys 57 (2003) 391-401
36. Brenner D.J. Hypofractionation for prostate cancer radiotherapy-What are the issues?. Int J Radiat Oncol Biol Phys 57 (2003) 912-914
37. Bentzen S.M., and Ritter M.A. The alpha/beta ratio for prostate cancer: What is it, really?. Radiother Oncol 76 (2005) 1-3
38. Thames H.D., Bentzen S.M., Turesson I., et al. Time-dose factors in radiotherapy: A review of the human data. Radiother Oncol 19 (1990) 219-235
39. Sachs R.K., and Brenner D.J. The mechanistic basis of the linear-quadratic formalism. Med Phys 25 (1998) 2071-2073
40. Brenner D.J., and Herbert D.E. The use of the linear-quadratic model in clinical radiation oncology can be defended on the basis of empirical evidence and theoretical argument. Med Phys 24 (1997) 1245-1248
41. Curtis S.B. Mechanistic models. Basic Life Sci 58 (1991) 367-382 366
42. Carlson D.J., Stewart R.D., Li X.A., et al. Comparison of in vitro and in vivo alpha/beta ratios for prostate cancer. Phys Med Biol 49 (2004) 4477-4491